Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
André J. Scheen. (2023) The current role of SGLT2 inhibitors in type 2 diabetes and beyond: a narrative review. Expert Review of Endocrinology & Metabolism 18:4, pages 271-282.
Read now
Read now
André J Scheen & Pierre Delanaye. (2022) Understanding the protective effects of SGLT2 inhibitors in type 2 diabetes patients with chronic kidney disease. Expert Review of Endocrinology & Metabolism 17:1, pages 35-46.
Read now
Read now
André J Scheen. (2020) Efficacy and safety profile of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease. Expert Opinion on Drug Safety 19:3, pages 243-256.
Read now
Read now
Articles from other publishers (23)
Niels Søndergaard Heinrich, Rune Ploegstra Pedersen, Mark Bitsch Vestergaard, Ulrich Lindberg, Ulrik Bjørn Andersen, Bryan Haddock, Tine Willum Hansen, Alessia Fornoni, Henrik Bo Wiberg Larsson & Peter Rossing. (2023) Evaluation of the effects of ezetimibe on albuminuria and kidney fat in individuals with type 2 diabetes and chronic kidney disease. Diabetes, Obesity and Metabolism 25:9, pages 2605-2615.
Crossref
Crossref
Mahyar Khazaeli, Ane C. F. Nunes, Yitong Zhao, Mahziar Khazaali, John Prudente, Nosratola D. Vaziri, Bhupinder Singh & Wei Ling Lau. (2023)
Tetrahydrocurcumin
Add‐On
therapy to losartan in a rat model of diabetic nephropathy decreases blood pressure and markers of kidney injury
. Pharmacology Research & Perspectives 11:2.
Crossref
Crossref
Masoumeh Hoseinian, Mahsa Mohebi, Zohreh Sadat & NedaMirbagher Ajorpaz. (2023) Effect of educating health promotion strategies model on self-care self-efficacy in elderly with kidney transplantation. Journal of Education and Health Promotion 12:1, pages 139.
Crossref
Crossref
Sharon Atkinson‐Briggs, Christopher Ryan, Anthony Keech, Alicia Jenkins & Laima Brazionis. (2022)
Nurse‐led vascular risk assessment in a regional Victorian Indigenous primary care diabetes clinic: An integrated Diabetes Education and Eye disease Screening [
iDEES
] study
. Journal of Advanced Nursing 78:11, pages 3652-3661.
Crossref
Crossref
Xinrui Jiang, Zhengji Zhang, Chunlu Li, Shijin Zhang, Qiang Su, Siyun Yang, Xin Liu, Ying Hu & Xiaofeng Pu. (2022) Efficacy and Safety of Non-Steroidal Mineralocorticoid Receptor Antagonists in Patients With Chronic Kidney Disease and Type 2 Diabetes: A Systematic Review Incorporating an Indirect Comparisons Meta-Analysis. Frontiers in Pharmacology 13.
Crossref
Crossref
André J Scheen & Pierre Delanaye. (2022) Acute renal injury events in diabetic patients treated with SGLT2 inhibitors: A comprehensive review with a special reference to RAAS blockers. Diabetes & Metabolism 48:2, pages 101315.
Crossref
Crossref
Pierre Delanaye, Karl Martin Wissing & Andre J Scheen. (2021) Sodium–glucose cotransporter 2 inhibitors: renal outcomes according to baseline albuminuria. Clinical Kidney Journal 14:12, pages 2463-2471.
Crossref
Crossref
Pierre Delanaye & Andre J. Scheen. (2021) The diuretic effects of SGLT2 inhibitors: A comprehensive review of their specificities and their role in renal protection. Diabetes & Metabolism 47:6, pages 101285.
Crossref
Crossref
André J. Scheen. (2021) Efficacy / safety balance of DPP-4 inhibitors versus SGLT2 inhibitors in elderly patients with type 2 diabetes. Diabetes & Metabolism 47:6, pages 101275.
Crossref
Crossref
Sadayoshi Ito, Naoki Kashihara, Kenichi Shikata, Masaomi Nangaku, Takashi Wada, Yasuyuki Okuda & Tomoko Sawanobori. (2021) Efficacy and safety of esaxerenone (CS-3150) in Japanese patients with type 2 diabetes and macroalbuminuria: a multicenter, single-arm, open-label phase III study. Clinical and Experimental Nephrology 25:10, pages 1070-1078.
Crossref
Crossref
Pierre Delanaye & Andre J. Scheen. (2021) Epidemiology of acute kidney injury adverse events with SGLT2 inhibitors: A meta-analysis of observational cohort studies. Diabetes Epidemiology and Management 3, pages 100021.
Crossref
Crossref
Matthew R Weir, April Slee, Tao Sun, Dainius Balis, Richard Oh, Dick de Zeeuw & Vlado Perkovic. (2021) Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program. Clinical Kidney Journal 14:5, pages 1396-1402.
Crossref
Crossref
Liang Wang, Pengfei Wang, Xiuyun Li, Yanyan Dong, Senmin Wu, Maosheng Xu, Xiu Chen, Shijia Wang, Chao Zheng & Chunpeng Zou. (2021) Combination CTLA-4 immunoglobulin treatment and ultrasound microbubble-mediated exposure improve renal function in a rat model of diabetic nephropathy. Aging 13:6, pages 8524-8540.
Crossref
Crossref
Alejandra Loyola-Leyva, Karen Hernández-Vidales, Juan Pablo Loyola-Rodríguez & Francisco Javier González. (2020) Raman spectroscopy applications for the diagnosis and follow-up of type 2 diabetes mellitus. A brief review. Biomedical Spectroscopy and Imaging 9:3-4, pages 119-140.
Crossref
Crossref
Sadayoshi Ito, Naoki Kashihara, Kenichi Shikata, Masaomi Nangaku, Takashi Wada, Yasuyuki Okuda & Tomoko Sawanobori. (2020) Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN). Clinical Journal of the American Society of Nephrology 15:12, pages 1715-1727.
Crossref
Crossref
André J. Scheen. (2020) Sodium–glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus. Nature Reviews Endocrinology 16:10, pages 556-577.
Crossref
Crossref
Miwa Morita & Keizo Kanasaki. (2020) Sodium–glucose cotransporter-2 inhibitors for diabetic kidney disease: Targeting Warburg effects in proximal tubular cells. Diabetes & Metabolism.
Crossref
Crossref
André J. Scheen. (2020) Pharmacokinetic/Pharmacodynamic Properties and Clinical Use of SGLT2 Inhibitors in Non-Asian and Asian Patients with Type 2 Diabetes and Chronic Kidney Disease. Clinical Pharmacokinetics 59:8, pages 981-994.
Crossref
Crossref
Giorgina Barbara Piccoli, Biagio Raffaele Di Iorio, Antoine Chatrenet, Claudia D’Alessandro, Marta Nazha, Irene Capizzi, Federica Neve Vigotti, Antioco Fois, Stefania Maxia, Patrick Saulnier, Gianfranca Cabiddu & Adamasco Cupisti. (2020) Dietary satisfaction and quality of life in chronic kidney disease patients on low-protein diets: a multicentre study with long-term outcome data (TOrino-Pisa study). Nephrology Dialysis Transplantation 35:5, pages 790-802.
Crossref
Crossref
Francesco Giorgino, Irene Caruso, Julia Moellmann & Michael Lehrke. (2020) Differential indication for SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with established atherosclerotic heart disease or at risk for congestive heart failure. Metabolism 104, pages 154045.
Crossref
Crossref
André J. Scheen. (2020) Series: Implications of the recent CVOTs in type 2 diabetes. Diabetes Research and Clinical Practice 159, pages 107726.
Crossref
Crossref
Engy A. Mahrous & Mohammed M. Nooh. 2020. Diabetes. Diabetes
195
202
.
Clara García-Carro, Ander Vergara, Irene Agraz, Conxita Jacobs-Cachá, Eugenia Espinel, Daniel Seron & María Soler. (2019) The New Era for Reno-Cardiovascular Treatment in Type 2 Diabetes. Journal of Clinical Medicine 8:6, pages 864.
Crossref
Crossref